These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 23813275)

  • 1. Lysins: the arrival of pathogen-directed anti-infectives.
    Pastagia M; Schuch R; Fischetti VA; Huang DB
    J Med Microbiol; 2013 Oct; 62(Pt 10):1506-1516. PubMed ID: 23813275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysin Therapy for Staphylococcus aureus and Other Bacterial Pathogens.
    Fischetti VA
    Curr Top Microbiol Immunol; 2017; 409():529-540. PubMed ID: 26728063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriophage lysins as effective antibacterials.
    Fischetti VA
    Curr Opin Microbiol; 2008 Oct; 11(5):393-400. PubMed ID: 18824123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens.
    Fischetti VA
    Int J Med Microbiol; 2010 Aug; 300(6):357-62. PubMed ID: 20452280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phage-derived lysins as therapeutic agents against multidrug-resistant Enterococcus faecalis.
    Gu J; Xi H; Cheng M; Han W
    Future Microbiol; 2018 Mar; 13():275-278. PubMed ID: 29441802
    [No Abstract]   [Full Text] [Related]  

  • 6. Bacteriophage lytic enzymes: novel anti-infectives.
    Fischetti VA
    Trends Microbiol; 2005 Oct; 13(10):491-6. PubMed ID: 16125935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phage-derived lysins as potential agents for eradicating biofilms and persisters.
    Sharma U; Vipra A; Channabasappa S
    Drug Discov Today; 2018 Apr; 23(4):848-856. PubMed ID: 29326076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Phage Lysins as Novel Therapeutics: A Historical Perspective.
    Fischetti VA
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29875339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LysSAP26, a New Recombinant Phage Endolysin with a Broad Spectrum Antibacterial Activity.
    Kim S; Jin JS; Choi YJ; Kim J
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33238548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant bacteriophage lysins as antibacterials.
    Fenton M; Ross P; McAuliffe O; O'Mahony J; Coffey A
    Bioeng Bugs; 2010; 1(1):9-16. PubMed ID: 21327123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EC300: a phage-based, bacteriolysin-like protein with enhanced antibacterial activity against Enterococcus faecalis.
    Proença D; Leandro C; Garcia M; Pimentel M; São-José C
    Appl Microbiol Biotechnol; 2015 Jun; 99(12):5137-49. PubMed ID: 25728445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the direct antimicrobial activity of Lysep3 against Escherichia coli by inserting cationic peptides into its C terminus.
    Ma Q; Guo Z; Gao C; Zhu R; Wang S; Yu L; Qin W; Xia X; Gu J; Yan G; Lei L
    Antonie Van Leeuwenhoek; 2017 Mar; 110(3):347-355. PubMed ID: 27943012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.
    Vázquez R; García E; García P
    Front Immunol; 2018; 9():2252. PubMed ID: 30459750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of Phage Lysins That Effectively Kill Pseudomonas aeruginosa in Mouse Models of Lung and Skin Infection.
    Raz A; Serrano A; Hernandez A; Euler CW; Fischetti VA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant Enterococcus faecalis infections.
    Cheng M; Zhang Y; Li X; Liang J; Hu L; Gong P; Zhang L; Cai R; Zhang H; Ge J; Ji Y; Guo Z; Feng X; Sun C; Yang Y; Lei L; Han W; Gu J
    Sci Rep; 2017 Aug; 7(1):10164. PubMed ID: 28860505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae.
    Díez-Martínez R; De Paz HD; García-Fernández E; Bustamante N; Euler CW; Fischetti VA; Menendez M; García P
    J Antimicrob Chemother; 2015; 70(6):1763-73. PubMed ID: 25733585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives.
    Borysowski J; Lobocka M; Międzybrodzki R; Weber-Dabrowska B; Górski A
    BioDrugs; 2011 Dec; 25(6):347-55. PubMed ID: 22050337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal surveillance on antibiogram of important Gram-positive pathogens in Southern China, 2001 to 2015.
    Xu Z; Xie J; Peters BM; Li B; Li L; Yu G; Shirtliff ME
    Microb Pathog; 2017 Feb; 103():80-86. PubMed ID: 27894963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.